Paul Neeson completed a PhD at the University of Melbourne (Pathology), before doing a post-doc in the Paterson lab (University of Pennsylvania) where he worked on B-cell lymphoma vaccines. He returned to Melbourne and established the human immunology translational lab (HITRL) in Cancer Immunology Research at the Peter MacCallum Cancer Centre. The Lab’s focus is on chimeric antigen receptor (CAR) T cells for solid tumors and human immuno-oncology. His lab has adopted ‘state of the art’ technologies to explore the immune context of human cancer. This information is being used to better understand immune escape, to stratify patients for immunotherapy combination treatments (including CART cells) for better outcomes in patients with solid tumors.